The private placement involves the issuance of pre-funded warrants to purchase approximately 37.2 million shares of common stock at a purchase price of $0.808 per warrant, alongside common stock purchase warrants with an exercise price of $0.683 per share. The closing of the private placement is anticipated to occur on March 31, 2026, subject to customary closing conditions.
In conjunction with this financing, Aprea also highlighted positive clinical data from its ongoing ACESOT-1051 trial, which evaluates APR-1051, a selective WEE1 kinase inhibitor. The trial has shown promising results, including a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer. This response was observed at a dose of 220 mg, indicating the drug's potential efficacy in biomarker-defined cancers.
The company is optimistic about the future of APR-1051, with plans to expand its clinical trials to include additional patient populations with high unmet medical needs. Aprea's management expressed confidence in the drug's ability to target WEE1 effectively while minimizing toxicity, which could position it as a best-in-class treatment option.
Overall, the successful financing and encouraging clinical results are expected to enhance Aprea's operational execution and strategic outlook, potentially leading to significant advancements in its drug development pipeline.
